Medical News Today: Hair follicles can be a site of origin for melanoma

Using a new mouse model of human melanoma, scientists show how the aggressive skin cancer can start in immature, pigment producing cells in hair follicles.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news

Related Links:

ConclusionsIn patients with RA, the relative increase in etanercept-associated risk of experiencing congestive heart failure, serious infection, non-melanoma skin cancer, or interstitial lung disease was similar between elderly and non-elderly.
Source: Drugs and Aging - Category: Geriatrics Source Type: research
AbstractNivolumab is a fully human monoclonal antibody that inhibits programmed cell death ‐1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal cancer, hepatocellular carcinoma, melanoma, non‐small cell lung cancer, renal cell carcinoma, or small cell lung cancer who rec eived nivolumab as monotherapy or in combination with ipilimumab or chemotherapy across 25 clinical studies. Nivolumab CL was similar across the tumor types examined; CL was higher for ipilimumab 1 mg/kg every 6 weeks (by 17%) and 3 mg/kg...
Source: CPT: Pharmacometrics and Systems Pharmacology - Category: Drugs & Pharmacology Authors: Tags: ARTICLE Source Type: research
AbstractIpilimumab is a fully human monoclonal antibody approved for the treatment of melanoma as monotherapy and for the treatment of melanoma, renal cell carcinoma, and colorectal cancer in combination with nivolumab. Ipilimumab time ‐varying clearance (CL) was assessed by a population pharmacokinetics (PPK) model developed using statistically significant covariates identified in a previous PPK analysis plus additional covariates. Data from 3,411 patients who received ipilimumab 0.3–10 mg/kg alone or in combination with niv olumab in 16 clinical trials were analyzed. Ipilimumab CL decreased over time; the ch...
Source: CPT: Pharmacometrics and Systems Pharmacology - Category: Drugs & Pharmacology Authors: Tags: ARTICLE Source Type: research
Publication date: Available online 9 November 2019Source: Materials Today CommunicationsAuthor(s): Felipe Alves Batista, Sabryna Brena Cunha Fontele, Lubna Karine Beserra Santos, Livia Alves Filgueiras, Steffane Quaresma Nascimento, João Marcelo de Castro e Sousa, Juan Carlos Ramos Gonçalves, Anderson Nogueira MendesAbstractThe development of systems for transport and release of drugs, also known as Drug delivery system (DDS), and are being used as strategies to combat cancer. These systems can maintain drug delivery at therapeutic levels and protect it from premature degradation in the biological environment...
Source: Materials Today Communications - Category: Materials Science Source Type: research
Publication date: Available online 8 November 2019Source: Artificial Intelligence in MedicineAuthor(s): Ni Zhang, Yi-Xin Cai, Yong-Yong Wang, Yi-Tao Tian, Xiao-Li Wang, Benjamin BadamiAbstractEarly detection of skin cancer is very important and can prevent some skin cancers, such as focal cell carcinoma and melanoma. Although there are several reasons that have bad impacts on the detection precision. Recently, the utilization of image processing and machine vision in medical applications is increasing. In this paper, a new image processing based method has been proposed for the early detection of skin cancer. The method ut...
Source: Artificial Intelligence in Medicine - Category: Bioinformatics Source Type: research
Both cell adhesion and matrix metalloproteinase (MMP) activity depend on pH at the cell surface. By regulating extracellular juxtamembrane pH, the Na+/H+ exchanger NHE1 plays a significant part in human melanoma ...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
Farzaneh Ioannis P. Trougakos Wolfgang Voelter Meletios-Athanasios Dimopoulos Aristotelis Bamias Ourania Tsitsilonis Prothymosin α (proTα) and its C-terminal decapeptide proTα(100–109) were shown to pleiotropically enhance innate and adaptive immune responses. Their activities have been broadly studied in vitro, focusing primarily on the restoration of the deficient immunoreactivity of cancer patients’ leukocytes. Previously, we showed that proTα and proTα(100–109) act as danger-associated molecular patterns (DAMPs), ligate Toll-l...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Skalnikova National cancer databases document that melanoma is the most aggressive and deadly cutaneous malignancy with worldwide increasing incidence in the Caucasian population. Around 10% of melanomas occur in families. Several germline mutations were identified that might help to indicate individuals at risk for preventive interventions and early disease detection. More than 50% of sporadic melanomas carry mutations in Ras/Raf/mitogen-activated protein kinase (MAPK/MEK) pathway, which may represent aims of novel targeted therapies. Despite advances in targeted therapies and immunotherapies, the outcomes in metasta...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Review Source Type: research
AbstractPurpose of reviewAs the treatment of many malignancies has improved, brain metastases (BM) have been observed as a site of the first recurrence in patients with controlled systemic cancers. This suggests that while the administered chemotherapy is effective against systemic cancer, drug concentrations in the central nervous system (CNS) are likely too low to be effective. These findings are in accord with data suggesting that more than 98% of FDA-approved drugs on the market today are unable to cross the blood-brain barrier (BBB).Recent findingsThis retrospective literature review was conducted to estimate the prop...
Source: Current Treatment Options in Neurology - Category: Neurology Source Type: research
Conditions:   Solid Tumor;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer;   Triple Negative Breast Cancer;   Small Cell Lung Cancer;   Metastatic Breast Cancer;   Malignant Melanoma;   Non Small Cell Lung Cancer;   Urothelial Carcinoma Interventions:   Drug: ZN-c3;   Drug: Talazoparib;   Drug: Pembrolizumab Sponsors:   K-Group Beta;   IQVIA Biotech Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Health | Melanoma | Skin | Skin Cancer